Oct 23, 2024 / 09:00AM GMT
Cecilia de Leeuw - C Rad AB - Chief Executive Officer, President
Welcome to our Q3 presentation. We had a challenging quarter, but let me kick off by zooming out of it.
Let me briefly take you through C-RAD's long-term strategy and our progress for Q3. C-RAD is active in the field of radiation therapy and approximately half of all cancer patients have radiation therapy as part of their treatment, and we continue to invest in our world-leading products.
C-RAD is in a very strong position with our whole portfolio of interfacing all major LINAC, Proton, and CT vendors. This is our most extensive interoperability portfolio ever.
C-RAD already today, has a global reach, but we are constantly looking into market expansions and we do this step by step. Growing our global presence is strengthening C-RAD's resilience.
And in the third quarter, we continue to see the result of our enhanced focus in the less mature Southeast Asian markets. We are ramping up our investment in Latin America where we had a successful training in connection with ASTRO, the MedTech show ASTRO, for
Q3 2024 C Rad AB Earnings Call Transcript
Oct 23, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers